drugset / Trial / NCT00789126

Single and Multiple Dose Escalation Study of VX-509 in Healthy Subjects

NCT00789126

Phase 1 Completed 72 enrolled Vertex Pharmaceuticals Incorporated
RandomizedDouble-blind

Summary

Study to evaluate the safety and tolerability of single ascending doses and multiple ascending doses of VX-509 administered to healthy male and female subjects

Timeline

Start
2008-10
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject decernotinib Small molecule

Indications

No indication recorded.